Stockscreener 앱 받기
104.75
0.26%
-0.27
시간 외 거래:
104.73
-0.02
-0.02%
전일 마감가:
$105.02
열려 있는:
$105.02
하루 거래량:
619.06K
Relative Volume:
1.14
시가총액:
$8.24B
수익:
-
순이익/손실:
$-425.38M
주가수익비율:
-17.90
EPS:
-5.8504
순현금흐름:
$-275.21M
1주 성능:
-0.28%
1개월 성능:
+6.96%
6개월 성능:
+16.86%
1년 성능:
+47.99%
1일 변동 폭
$103.84
$106.73
1주일 범위
$99.78
$107.14
52주 변동 폭
$63.55
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
104.75 | 8.26B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Wells Fargo | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Nuvalent (NUVL) CSO Pelish sells $323k in shares By Investing.com - Investing.com India
Nuvalent (NUVL) CSO Pelish sells $323k in shares - Investing.com
Nuvalent (NUVL) CSO Pelish exercises options, sells 3,093 shares under plan - Stock Titan
(NUVL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Portfolio Update: Is Nuvalent Inc in a consolidation phase2026 Market Mood & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
What Nuvalent (NUVL)'s FDA NDA Filing for Neladalkib in ALK-Positive NSCLC Means For Shareholders - simplywall.st
Nuvalent CEO Sells Over $3 Million in Stock - National Today
Nuvalent (NUVL) CEO trades 30K shares after option exercises - Stock Titan
Wedbush Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Nuvalent Submits NDA for Neladalkib in ALK+ NSCLC After TKIs - Oncology Nursing News
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $142 - Moomoo
Nuvalent Announces Submission of New Drug Application to FDA for - GuruFocus
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC - The Malaysian Reserve
Nuvalent Files FDA Application for Lung Cancer Therapy - TipRanks
Nuvalent Submits New Drug Application to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer - Minichart
Nuvalent submits new drug application to FDA for neladalkib in advanced lung cancer - Investing.com
Nuvalent Announces Submission Of New Drug Application To FDA For Neladalkib In Tki Pre-Treated Advanced Alk-Positive Nsclc - TradingView — Track All Markets
Nuvalent (NUVL) submits FDA New Drug Application for neladalkib in ALK+ lung cancer - Stock Titan
Aberdeen Group plc Increases Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Truist Financial Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $140 - Moomoo
NUVL PE Ratio & Valuation, Is NUVL Overvalued - Intellectia AI
Nuvalent CFO Sells $1.2M in Shares - National Today
Nuvalent (NASDAQ:NUVL) CFO Alexandra Balcom Sells 11,430 Shares - MarketBeat
Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $116 - Moomoo
Nuvalent Insider Sold Shares Worth $537,943, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan - Stock Titan
Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $135 - moomoo.com
Price-Driven Insight from (NUVL) for Rule-Based Strategy - Stock Traders Daily
Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch - Investing.com Australia
Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch By Investing.com - Investing.com South Africa
22,000 Class A shares proposed sale — NUVL (NASDAQ: NUVL) - Stock Titan
Nuvalent Insider Sold Shares Worth $542,991, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO exercises 5.5K options, sells 5.5K shares under 10b5-1 - Stock Titan
Nuvalent Initiated at Overweight by Wells Fargo - Moomoo
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential By Investing.com - in.investing.com
Wells Fargo initiates Nuvalent stock with overweight rating on drug potential - Investing.com India
Nuvalent (NASDAQ:NUVL) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Nuvalent at Overweight With $116 Price Target - marketscreener.com
Wells Fargo Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $116 - Moomoo
Upcoming AACR 2026 event announcement sees Nuvalent stock down 1.43% - Traders Union
Weekly Trades: Should I set a stop loss on Nuvalent IncQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Nuvalent (NUVL) ownership listed as 0 - Stock Titan
Nuvalent (NUVL) CFO sells 25,130 shares in Rule 10b5-1 trades - stocktitan.net
S&P 500 Futures Drop In Premarket Trading; Nuvalent, Figure Tech Solns Lead - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan
ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma Companies Advance Next-Generation Therapies | DelveInsight - Barchart.com
Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):